Young Su Noh

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Ivana Yen, Jeeyun Lee, Yong Sang Hong et al. · Nature · 2021 · 133 citations · Full text

Raf Inhibitor Belvarafenib, Melanoma, Pathology +6

Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.

Tae Won Kim, Jeeyun Lee, Sang Joon Shin et al. · Journal of Clinical Oncology · 2019 · 46 citations

Chemoprevention Strategy, Quantitative Pharmacology, Solid Tumor Patients +19

Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study

Keunchil Park, Pasi A. Jänne, Dong‐Wan Kim et al. · Cancer · 2021 · 33 citations · Full text

A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion.

Sang Joon Shin, Jeeyun Lee, Tae Min Kim et al. · Journal of Clinical Oncology · 2021 · 29 citations

Phase Ib Trial, Pharmacotherapy, Metronomic Therapy +17

Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial

Dong‐Wan Kim, Dae Ho Lee, Ji‐Youn Han et al. · Lung Cancer · 2019 · 28 citations

Oncology, Single Arm, Medicine +8